뉴스벤징가
AstraZeneca Says Rare Disease Drug Shows Improvements in Inherited Bone Disorder Despite Missing Key Trial Goal
· 발표
기사 요약
AstraZeneca releases Phase 3 HICKORY trial data for efzimfotase alfa in hypophosphatasia (HPP), showing key secondary improvements.
기사 원문에서 발췌했어요.
댓글 —
댓글을 불러오고 있어요…